Abstract Library

#4374 Efficacy and safety of immunotherapy combined with antiangiogenesis agents and temozolomide in neuroendocrine carcinoma

Introduction: Platinum-based doublet chemotherapy is the standard first-line treatment, without standard treatment for second-line or subsequent systemic therapy for recurrent or progressive advanced neuroendocrine cancer (NEC).

Conference:

Presenting Author:

Authors: Li X, Yang M, Fan Q, Song L,

Keywords: Neuroendocrine carcinoma, Immunotherapy, Antiangiogenesis agents, Temozolomide,

#3095 Clinical observation of PD-1 inhibitor combined with anlotinib in the treatment of advanced neuroendocrine carcinoma

Introduction: Clinical observation of PD-1 inhibitor combined with anlotinib in the treatment of advanced neuroendocrine carcinoma.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Song L, Yu X,

Keywords: immune checkpoint inhibitor, anlotinib, neuroendocrine carcinoma,

#72 Reduced expression of p27 and the occurrence of CpG island methylator phenotype in insulinomas

Introduction: The molecular pathogenesis of sporadic insulinoma is unclear, though some of the genes were found to be slienced by promoter methylation. CpG island methylator phenotype (CIMP) was found in a number of common tumors and correlated with loss of expression of p27, which may contribute to the tumorigenesis of the tumors.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Chen Y

Authors: Chen Y, Zhou Q, Xiao Y, Zhu Y, Liu T,

Keywords: insulinoma, p27 gene, promoter methylation, CpG island methylator phenotype ,